» Articles » PMID: 38003814

Cervical HPV Infections, Sexually Transmitted Bacterial Pathogens and Cytology Findings-A Molecular Epidemiology Study

Abstract

Prevalent cervical HPV infection and high-risk HPV persistence consequences have been extensively investigated in the literature; nevertheless, any causative interrelations of other sexually transmitted bacterial infections (STIs) with cervical HPV infection have not yet been fully elucidated. This study aimed to investigate the possible association of STIs with cervical cytology aberrations and HPV genotyping results in a representative sample of predominantly young Greek women. Liquid-based cytology and molecular detection for bacterial STIs and HPV as well as extended HPV genotyping were simultaneously assessed in cervical samples from 2256 individuals visiting several urban outpatient Gynecology Departments for well-woman visits or cervical screening throughout a 20-month period. All specimens were centrally processed with validated molecular assays. The mean age of the studied women was 37.0 ± 11.7 years; 722 women (33.30%) tested positive for STI (mean age 34.23 ± 10.87 years). A higher mean age (38.34 ± 11.83 years ( < 0.05)) was associated with negative STI testing. was detected in 59 individuals (8.2%), in 156 (21.6%), in 14 (1.9%), and spp. in 555 (76.9%); infections with two bacterial pathogens were identified in 73 samples (10.1%). Cervical HPV was detected in 357 out of 1385 samples with a valid HPV typing result (25.8%). The mean age of HPV-positive women was 32.0 ± 8.4 years; individuals testing HPV-negative were slightly older (N = 1028): 34.4 ± 9.2 ( < 0.05). Among the 1371 individuals with valid results both for bacterial STIs and cervical HPV detection, women with an HPV-positive sample were more likely to harbor an STI (OR: 2.69, 95% CI 2.10-3.46, < 0.05). Interestingly, bacterial STI positivity illustrated significant heterogeneity between NILM and LSIL cases, with 28.88% of NILM and 46.33% of LSIL cases harboring an STI, respectively ( < 0.05). In brief, in a population with a high prevalence for STIs, especially spp., an association was documented between bacterial pathogen detection and cervical HPV infection, as well as abnormal cytology; these findings merit further investigation.

Citing Articles

Evaluating HPV Viral Load and Multiple Infections for Enhanced Cervical Cancer Risk-Based Assessment.

Varesano S, Ciccarese G, Paudice M, Mazzocco K, Gaggero G, Ferrero S Life (Basel). 2025; 15(2).

PMID: 40003564 PMC: 11856100. DOI: 10.3390/life15020153.


Could APTIMA mRNA Assay Contribute to Predicting Cervical Bacterial Sexually Transmitted Co-Infections? A Colposcopy Population Study.

Valasoulis G, Pouliakis A, Magaliou I, Papoutsis D, Daponte N, Margioula-Siarkou C Int J Mol Sci. 2024; 25(23).

PMID: 39684856 PMC: 11642188. DOI: 10.3390/ijms252313146.


Effect of metabolic syndrome and its components on the risk and prognosis of cervical cancer: A literature review.

Kajabwangu R, Izudi J, Bazira J, Ssedyabane F, Turanzomwe S, Birungi A Gynecol Oncol Rep. 2024; 54:101438.

PMID: 39035032 PMC: 11260376. DOI: 10.1016/j.gore.2024.101438.


Aerobic vaginitis is associated with carbonic anhydrase IX in cervical intraepithelial neoplasia.

Grinceviciene S, Vaitkiene D, Kanopiene D, Vanseviciute Petkeviciene R, Sukovas A, Celiesiute J Sci Rep. 2024; 14(1):8789.

PMID: 38627429 PMC: 11021548. DOI: 10.1038/s41598-024-57427-x.

References
1.
Mandelblatt J, Lawrence W, Womack S, Jacobson D, Yi B, Hwang Y . Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002; 287(18):2372-81. DOI: 10.1001/jama.287.18.2372. View

2.
Bjartling C, Osser S, Persson K . The association between Mycoplasma genitalium and pelvic inflammatory disease after termination of pregnancy. BJOG. 2009; 117(3):361-4. DOI: 10.1111/j.1471-0528.2009.02455.x. View

3.
Jensen J . Mycoplasma genitalium: the aetiological agent of urethritis and other sexually transmitted diseases. J Eur Acad Dermatol Venereol. 2003; 18(1):1-11. DOI: 10.1111/j.1468-3083.2004.00923.x. View

4.
Verteramo R, Pierangeli A, Mancini E, Calzolari E, Bucci M, Osborn J . Human Papillomaviruses and genital co-infections in gynaecological outpatients. BMC Infect Dis. 2009; 9:16. PMC: 2656516. DOI: 10.1186/1471-2334-9-16. View

5.
Ciavattini A, Delli Carpini G, Giannella L, Arbyn M, Kyrgiou M, Joura E . European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic. Int J Gynecol Cancer. 2020; 30(8):1097-1100. PMC: 7418593. DOI: 10.1136/ijgc-2020-001617. View